top of page

DEA Administrator ‘Did Not Sign Off’ On Marijuana Rescheduling Order, Prohibitionist Group Says

  • Writer: Bob Marley
    Bob Marley
  • May 6, 2024
  • 4 min read

The leader of a marijuana prohibitionist organization that accurately predicted last week’s cannabis rescheduling recommendation now says that sources inside the Drug Enforcement Administration (DEA) are telling him that Anne Milgram, the agency’s administrator, “did not sign off” on the landmark decision.

“I can now say with full confidence that the Administrator of DEA, Anne Milgram, did NOT sign the rescheduling order,” Kevin Sabet, president of the advocacy group Smart Approaches to Marijuana (SAM), posted on social media Monday, citing “two confidential sources inside DEA and another outside DEA with intimate knowledge.”

He said in a further statement, relayed on The Drug Report, a news site published by the Foundation for Drug Policy Solutions—which was co-founded by Sabet—that “it’s hard to overstate how deeply political and flawed this makes the rescheduling process look.”

“DEA Administrator Anne Milgram should be commended for standing up for science and truth, over the profit-driven pot industry,” said Sabet, who served under three presidents as an Office of National Drug Control Policy advisor. “Her courage will show she was on the right side of history. It’s equally hard to overstate what a botched process the Biden Administration’s rescheduling review has been from the outset. This unprecedented action by the Attorney General reflects a process poisoned by political considerations and conducted with a pre-determined outcome.”

SAM recently sent out a fundraising email following the rescheduling announcement, saying explicitly that the group is looking into taking legal action in an effort to halt the federal reform.

BIG: I can now say with full confidence that the Administrator of DEA, Anne Milgram, did NOT sign the rescheduling order, breaking with five decades of precedent and established law and regulations (two confidential sources inside DEA and another outside DEA with intimate…

— Kevin Sabet (@KevinSabet) May 6, 2024


If true, the significance of Sabet’s claim that Milgram didn’t sign off on the rescheduling decision isn’t immediately clear. Asked one reply on social media: “Do you have confirmation this was done in protest or just that Anne Milgram wasn’t the one to sign it?”

If Milgram did not in fact sign the reform document, it’s also not clear who did. It could be the case that a lower-ranking DEA official is the signatory. Alternatively, it could be signed by U.S. Attorney General Merrick Garland, perhaps signaling how high of a priority for the administration the marijuana move is.

In a statement to Marijuana Moment last week, Department of Justice (DOJ) Director of Public Affairs Xochitl Hinojosa said that “the Attorney General circulated a proposal to reclassify marijuana from Schedule I to Schedule III.”

“Once published by the Federal Register,” Hinojosa added, “it will initiate a formal rulemaking process as prescribed by Congress in the Controlled Substances Act.”

The next step in the rescheduling process would be for the White House Office of Management and Budget (OMB) to review the rule. If approved, it would go to public comment before potentially being finalized.

DEA did not provide comment regarding Sabet’s assertions in response to a request from Marijuana Moment.

Milgram is scheduled to appear at a congressional budget hearing on Tuesday morning to discuss the agency’s funding request for fiscal year 2025.

The Drug Report post anticipates that she’ll “likely be met with questions from lawmakers about the DEA’s decision to reschedule marijuana and her agency’s process for coming to that conclusion.”

Later this year, another DEA representative, William Heuett, is set to present on the agency’s “processing of schedule I research applications” at a federal research meeting on the potential for marijuana to treat pain. It’s not clear how that presentation might be updated in light of the ongoing rescheduling process.

Meanwhile in the wake of the DEA rescheduling announcement, a former head of the agency said the proposal is “understandable” because it “reflects the reality” of public opinion toward the medical value of cannabis.

In an interview with Fox News last week week, former DEA Administrator Asa Hutchinson said it “absolutely looks like” the agency will follow through with moving marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

“Whenever we see over a dozen states now have medical marijuana, clearly there’s a movement for reclassification,” he said. “And so it’s not a surprise to me.”

“I think it reflects the reality of today’s both culture but also the public sentiment. That’s most significant,” said Hutchinson, a Republican who also served as governor of Arkansas.

Separately, the top Democrat in the U.S. House said last week that the Biden administration’s move to reschedule marijuana is a “step in the right direction,” but it should be followed up with congressional action such as passing the legalization bill Senate Majority Leader Chuck Schumer (D-NY) filed.

On the opposite side of the spectrum, a Republican senator said that marijuana is a “gateway drug,” and Democrats’ moves to legalize it reflect “pro-criminal, anti-American policies” that will “stimulate more crime on American streets.” He also argued that cannabis banking legislation “facilitates an entire infrastructure and an ecosystem for more drug usage in America.”

Biden Should Release People In Prison For Marijuana, Criminal Defense Lawyers Group Tells White House

Comments


Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page